DBV Technologies SA Sponsored ADR

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company can now move forward with a late-stage study of its lead pipeline candidate.

Why DBV Technologies Stock Is Soaring Today

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

DBVT was recently downgraded by Goldman Sachs. It is trading lower on any timeframe you consider and hence makes a good tax loss buy candidate.

DBV Technologies: Downgrade And Tax Loss Selling Create A Buying Opportunity

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

DBV Technologies S.A. (NASDAQ:DBVT ) Q3 2022 Earnings Conference Call November 4, 2022 5:00 PM ET Company Participants Anne Pollak – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Conference Call Participants Jon Wolleben – JMP Securities Clément Bassat – Portzamparc Jacob Mekhael – Kempen Matthew Caufield – H.C.

DBV Technologies S.A. (DBVT) Q3 2022 Earnings Call Transcript

DBV Technologies Reports Third Quarter Financial Results and Business Update

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether DBV and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of DBV Technologies S.A. - DBVT

DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA.

DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

DBV Technologies to Present at Upcoming Investor Conferences

Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

DBV Technologies Reports Second Quarter 2022 Financial Results

DBV Technologies is a French company traded on Nasdaq which is developing treatments for food allergies. Their technology is a patch that delivers a very small daily dose of the allergen to desensitize the patient.

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

Axsome Therapeutics

Let's consider the risk-reward profile of these companies before jumping on the bandwagon.

2 Biotechs That Recently Soared -- Are They Buys?

DBV Technologies to Participate in Upcoming EAACI 2022 Congress

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

The French biotech kept its upward momentum going with news of nearly $200 million in fresh funding.

Why DBV Technologies Stock Popped Again Today

Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?

DBV Technologies Announces Private Placement Financing of $194 Million

Its peanut allergy patch tests quite well in very young patients.

Why DBV Technologies Was a Big Winner on Wednesday

HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage of treatment responders in the active compared to the placebo arm.

HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?

News for DBV Technologies SA Sponsored ADR Stock (DBVT)